Scholarlink

Purpose <p>To investigate the efficacy and feasibility of PD-1 antibody combined with concurrent chemoradiotherapy in patients with esophageal cancer.</p> Methods <p>From July 2020 to October 2023, 15 patients with esophageal cancer in Zhejiang Quhua Hospital were treated with PD-1 monoclonal antibody after concurrent chemoradiotherapy. The incidence of adverse reactions was recorded throughout the treatment period. The Kaplan-Meier survival analysis was used to estimate median overall survival (OS) and progression-free survival (PFS).</p> Results <p>All 15 patients were enrolled, with a median follow-up of 23.0 months (ranging from 6.0 to 37.5 months). The 1-year OS rate was 93.3%, and the 2-year OS rate was 46.7%. No treatment-related deaths were reported.</p> Conclusion <p>Concurrent chemoradiotherapy combined with PD-1 antibody yielded encouraging survival outcomes in patients with esophageal cancer, and this regimen deserves further clinical exploration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月22日

查看全文
  • Chunxiu Hu,
  • Yi Liu,
  • Zhengqi Yang,
  • Qin Chen,
  • Yuefang Tong,
  • Bin Da,
  • Yuefei Sun,
  • Huiting Rao

摘要

Purpose

To investigate the efficacy and feasibility of PD-1 antibody combined with concurrent chemoradiotherapy in patients with esophageal cancer.

Methods

From July 2020 to October 2023, 15 patients with esophageal cancer in Zhejiang Quhua Hospital were treated with PD-1 monoclonal antibody after concurrent chemoradiotherapy. The incidence of adverse reactions was recorded throughout the treatment period. The Kaplan-Meier survival analysis was used to estimate median overall survival (OS) and progression-free survival (PFS).

Results

All 15 patients were enrolled, with a median follow-up of 23.0 months (ranging from 6.0 to 37.5 months). The 1-year OS rate was 93.3%, and the 2-year OS rate was 46.7%. No treatment-related deaths were reported.

Conclusion

Concurrent chemoradiotherapy combined with PD-1 antibody yielded encouraging survival outcomes in patients with esophageal cancer, and this regimen deserves further clinical exploration.